| 摘要 |
Use of nucleotide (nt) sequences (I) containing one or more GRU (glucocorticoid response unit, mineralocorticoid, androgen or progestagen) and/or ERU (estrogen response unit) for in vitro detection of 'xenohormones' and for preparing compositions for treating disorders associated with activity of receptors for the specified hormones. The response units contain two elements (designated GRE or ERE) that overlap such that the center of one element is shifted by 5 bp relative to the center of the other element. GRE are derived by altering one or more nt in the following sequence 5'GGTACAX1X2X3TGTTCT3', and 3'CCATGTX4X5X6ACAAGA5'. X1, X2 and X3 = any nt; X4, X5 and X6 = any nt able to pair with X1, X2, or X3 ERE are derived by altering one or more nt in the following sequence, 5'AGGTCAX1X2X3TGACCT3' (III), and 3'TCCACTX4X5X6ACTGGA5'. Independent claims are also included for the following: (a) sequence (IA) comprising at least two of the components GRE A and/or GRE A up (where upper case indicates nt involved in the response element;): 5'GGTACAgaaAGACCTgttct3' (GRE A); 3'ccatgTCTTTCggACAAGA5' (GRE A); 5'GGTACAgtaCGTCCTgttct3' (GRE A up); and 3'ccatgTCATGCaggACAAGA5' (GRE A up); (b) sequence (Ib) containing as ERU sequence (V), (where all X and x represent nt, or their derivatives, able to form pairs between the strands, or a succession of (II) units, spaced at a distance of 10n-11n bp, center to center, with n = integer of 2 or more;): (i) 5'Xa1GGTCXb1ggtCGACCXc1gaccxd1; and (ii) 3'xa2ccagXb2CCAGCtggXc2CTGGXd2; (c) vector, particularly a plasmid, containing (Ib); (d) human or animal cell transformed with this vector; and (e) gene therapy vectors containing at least one GRU and/or ERU as defined.
|
